Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
详细信息 查看全文
- 作者：Yajnavalka Banerjeea ; yaj.banerjee@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Raul D. Santosb ; Khalid Al-Rasadic ; Manfredi Rizzod ; e
- 关键词：PCSK9 ; LDL-C ; LDL-receptor ; VLDL ; PCSK9-Centric lipid lowering ; Pleiotropic ; Monoclonal antibody ; CRISPR-CAS9 ; Anti-sense oligonucleotide ; Peptide-mimetic ; Adnectin ; Vaccine ; Lipoprotein-apheresis
- 刊名：Atherosclerosis
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：248
- 期：Complete
- 页码：62-75
- 全文大小：1610 K
文摘
- •
Several lipid lowering strategies targeting PCSK9 have been designed to manage hypercholesterolemia.
- •
PCSK9 mediates several physiological effects, which are independent of cholesterol homeostasis.
- •
Long-term PCSK9 inhibition may detrimentally affect these physiological effects and therefore should be carefully evaluated.